Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7887064 | 1.00 | LMNA (0.59) | LMNAPOLBALDH1A1KMT2ACYP3A4 | |
| SCHEMBL20788118 | 1.00 | LMNA (0.59) | LMNAPOLBALDH1A1KMT2ACYP3A4 | |
| SCHEMBL13646612 | 1.00 | LMNA (0.59) | LMNAPOLBALDH1A1KMT2ACYP3A4 | |
| SCHEMBL7887070 | 1.00 | LMNA (0.59) | LMNAPOLBALDH1A1KMT2ACYP3A4 | |
| SCHEMBL13650799 | 1.00 | LMNA (0.59) | LMNAPOLBALDH1A1KMT2ACYP3A4 | |
| SCHEMBL13038857 | 1.00 | LMNA (0.59) | LMNAPOLBALDH1A1KMT2ACYP3A4 | |
| SCHEMBL14468743 | 1.00 | LMNA (0.59) | LMNAPOLBALDH1A1KMT2ACYP3A4 | |
| SCHEMBL23069384 | 0.89 | LMNA (0.62) | LMNAPOLBALDH1A1KMT2ACYP3A4 | |
| SCHEMBL10719671 | 0.89 | LMNA (0.53) | LMNAPOLBALDH1A1KMT2ACYP3A4 | |
| SCHEMBL21195779 | 0.88 | LMNA (0.47) | LMNAPOLBALDH1A1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20220281911-A1 | OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE | BOOTSTRAP EUROPE 3.0 S.À R.L. (LU) | 2022-09-08 | — | — | US | disclosed |
| EP-4017539-A1 | OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE | MiNA Therapeutics Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| US-20220023325-A1 | SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2022-01-27 | — | — | US | disclosed |
| US-20210128594-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-05-06 | — | — | US | disclosed |
| US-10668092-B2 | Compositions and methods for treatment of inflammatory disorders | THE JOHN HOPKINS UNIVERSITY (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3558323-A1 | SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA | Etablissement Français du Sang (FR) | 2019-10-30 | — | — | EP | disclosed |
| US-20190077874-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBEROUS SCLEROSIS | National Tuberous Sclerosis Association, Inc. | 2019-03-14 | — | — | US | disclosed |
| US-20180280418-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | THE JOHNS HOPKINS UNIVERSITY | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280418-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | TLR4, TLR3, TLR2 | LMNA 2016/4885POLB 4193/4885ALDH1A1 3398/4885 |
| US-20220281911-A1 | OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE | SARNP, DCLRE1B, RNGTT | LMNA 2008/4885POLB 575/4885ALDH1A1 3002/4885 |
| US-20220023325-A1 | SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA | TLR4, TLR3, TLR2 | LMNA 2057/4885POLB 4797/4885ALDH1A1 4496/4885 |
| US-10668092-B2 | Compositions and methods for treatment of inflammatory disorders | TLR4, TLR3, TLR2 | LMNA 2016/4885POLB 4193/4885ALDH1A1 3398/4885 |
| US-20210128594-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | TLR4, TLR3, TLR2 | LMNA 2016/4885POLB 4193/4885ALDH1A1 3398/4885 |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | LMNA 3350/4885POLB 4359/4885ALDH1A1 2349/4885 |
| US-20190077874-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBEROUS SCLEROSIS | TLR4, TLR3, TLR2 | LMNA 1227/4885POLB 3761/4885ALDH1A1 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.